On February 25, 2022 Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and an Australian leader in cell therapy, reported that the first patient in dose level 3 of the phase 1 CHM 1101 (CLTX CAR T) clinical trial in recurrent/ progressive glioblastoma has now initiated therapy at City of Hope, one of the largest cancer research and treatment organizations in the United States (Press release, Chimeric Therapeutics, FEB 25, 2022, View Source [SID1234609034]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patients in this dose level will receive a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cells through dual routes of intratumoral and intraventricular administration. Advancement to this dose level has come about rapidly following on the completion of the 2nd dose cohort without any dose limiting toxicities in December 2021.
"We are very pleased with the continued progress of the trial," said Jennifer Chow, Chimeric Therapeutics Chief Executive Officer. "With the encouraging safety and activity signs shown in the lower two dose levels we are excited to be advancing to the higher dose levels that may provide more therapeutic benefit to patients with progressive or recurrent glioblastoma."
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHLOROTOXIN CAR T
Chlorotoxin CAR T (CLTX CAR T) cell therapy is a first and best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent/ progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.
CLTX CAR T cell therapy uniquely utilizes chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR). CLTX and CLTX CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.
In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.